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Summary
We studied the inhibitory effect of pentosan polysulphate
(PPS, Hémoclar@) on thrombin formation in blood coagulation.
In contrast to a current hypothesis (1) the antithrombin III
independent effect of PPS on blood coagulation is not caused by
preventing the binding of the factors lX, lxn, X, X,, VIII, V V"
and II onto procoagulant phospholipids.
We investigated the activation by thrombin of factors I, V and
VIII. A strong inhibitory effect of PPS on factor VIII activation
could be observed. Inhibition of the activation of factor V to the
same extent requires about 30-fold higher concentrations of PPS,
whereas the activation (clotting) of fibrinogen is not inhibited.
The effect of PPS on factor VIII" is two-fold: A) it inhibits its
formation and B) it inhibits its function probably by the formation
of a factor VIII,,-PPS complex.
Prothrombinase, constituted of purified factors Xo, Vo and
phospholipids was not inhibited by PPS, neither were incomplete
forms of this enzyme, lacking phospholipids or factor V". The
complete factor X activating enzyme (factors IX,,, VIII" and
phospholipids), however, was strongly inhibited, but incomplete
forms, lacking factor VIII, were not. The inhibition of the
complete enzyme can be explained by reversible binding of PPS to
factor VIII. (causing an inhibition of its function) and it is not an
effect on the enzymatic function of the complete enzyme. On
saturation of the enzyme witb an excess of factor VIII. no
inhibition by PPS is noticed.
We postulate therefore that the antithrombin III independent
inhibitory effect of PPS on thrombin generation on blood
coagulation is by interaction with factor VIII.. This effect is
additional to the heparinlike action of PPS, i. e. potentiation of
the activity of antithrombin III and/or heparin cofactor II. At
This work was financially supported by the "Centre de Recherches
Clin-Midy" and "La Fondation de France"
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s2238, H-D-phenylalanyl-L-pipecolyl-L-arginine-p-nitro-anilide-
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concentrations attained during therapeutic use the action of
pentosan polysulphate on factor VIII, is the only one that will
significantly inhibit the coagulation mechanism.
lntroduction
Pentosan polysulphate (PPS) or Hémoclar@ is a mixture of
polysaccharides that is obtained by sulphation of pentosans
extracted lrom beech wood shavings (2) Its average molecular
weight is 4,500 (2). Soria et al (3) and Scuily et al. (4) have shown
that PPS shows some similarities with low molecular weight
heparin as to its inhibitory effect on blood coagulation. Both
compounds are dependent upon antithrombin III for factor Xu
and thrombin inhibiting activities (3, 4) Pentosan polysulphate
also is a good activator of heparin cofactor II (2). Apart from
that, PPS inhibits the partial thromboplastin time independently
of anti thrombin II I  (1, 3). Dunn et al.  (5) have shown that both
heparin and PPS increase the binding of fibrinogen to ADP-
treated platelets. Fischer et al. (1) showed that PPS inhibits the
factor X" generzrtion in defibrinated plasma triggered by contact
activation as well as by purified factor IX,,. This suggests that PPS
does not act on the contact system, but interferes with factor X
activation at the level of factor IX" Both Ofosu et al. (6) and
Walker and Esmon (7) have suggested that antithrombin III
independent effects of heparin are due to inhibition of phos-
pholipid binding. Fischer et al. (1) suggest that PPS acts by the
same mechanism, presumably even more effective than heparin,
because of its greater negative charge. Another suggested
mechanism is inhibition of thrombin dependent factor V activa-
tion and thereby inhibiting the prothrombinase complex (8).
From the literature it is clear that the site of inhibition of blood
coagulation by PPS has not been determined unequivocally.
Possible sites of action are: The activation of prothrombin by
prothrombinase (factor Xo, factor V" and phospholipid) and the
activation of factor X by its activating enzyme (factor IXu,
factor VIII. and phospholipid). This inhibition might be mediated
by either impairment of the binding of ciotting factors to
phospholipids or direct action on thrombin in the activation of
one more of the factors I. V. and VIII.
Materials and Methods
Materials
Human congenital factor VIII deficient plasma was a gift from T.
Repucci, Centre de Tiansfusion, Liège, Belgium The plasma was from a
patient with less than 1'lo factor VIII. The btood (450 ml) was collected in
a bag containing CPDA-formula 1 (63 ml, containing 2 g dextrose mono-
hydrate, 1 66 g sodium citrate, 206 mg citric acid, 158 mg sodium acid
phosphate, 17 3 mg adenine) The blood was centrifuged at 5,000 x g
during 15 min at 4" C The plasma was frozen at -80" C before use.
Bovine factors V and V" were a gift from Dr. T Lindhout 52337, 52238,
RW-X and human fibrinogen (grade L) were purchased from AB Kabi
Diagnostica, Stockholm, Sweden. STI, HSA (essentially fatty acid free),
heparin (sodium salt) and Echis carinatus venom were obtained from
Sigma Sephadex G50, DEAE-Sephadex and SP-Sephadex were from
Pharmacia, Tiasylol was from Bayer Actin activated cephaloplastin 25% DOPS and75"k DOpC usrng an MSE Mark II 150-Watt ultrasonic
reagent was from Dade Diagnostics and Reptilase from Boehringer disintegrator, set at 9 p peak to peak amplitucle, or by the ether-injectionMannheim Hémoclar was a gift of the Laboratoires Clin Midy, Paiis, method according to van tle steen et al (23) and Deamer and BanghamFrance' (24). By injection of 2 ml ether, containing 3 pmol DOpC and 1 pmolAll other reagents used, were of the highest grade commercially oCjpS into + ml warm (60. C) buffer (175 mM NaCl, 50 mM Tïis-HCl;
available pH19) large unilameliu. u..i.I", were obtained The vesicles were
dialyzed against the same buffer to remove traces of ether To concentrâte
Prctteins the vesicles and to remove small vesicles which cannot be spun down, they
Bovine racrorlX was puriiïed according to Fuiik_awa er ar (e) ff::Jï:1i:i.1'"1',';33ÎÀti,iïÏ3",1,?;ïlr.:i'.ili,ïï:î:,i::
Factor IX, was prepared by incubating bovine factor IX with purified were spun down Finally the pellet was taken up into a sinall amount of
contact product (10, 11) according to Fujikawa et al (12) buffer These vesicles were,used in the binding itudies
Bovine factors X, and X2 were prepared according to Fujikawa et al. Phospholipi<1 concentrations were determined by analysis of the(13) The two forms of factor X were well separated In this study phosphate content (25)
factor X, is used, which is not indicated further. No thrombin or factor f^
could be detected in our factor X preparations as determined with the
chromogenic substrates 52238 and S13j7, respectively. Bovine prothrom- Rinrling Experiments
bin was purified as described by Owen et al (14) Thrombin wai prepared Binding of clotting factors to large unilamellar vesicles was measurecl inby incubating 5 pM prothrombin with 10 pM phospholipid vesicles(25% the following way. Ôlotting factors (20-l0L) nM) were incubated in rhebrain PS, 75% yolk PC), 10 mM CaClr, 30 nM factor-X, and 21 nM presence of 5 mM CaCl, wrth various concentrations of large-votume-factor V" during 40 min at37" C in a buffer containing 40 mM MES-Tiis vesicles containing 25% DOPS and75./" DOPC. Then the vesicles were
and 100 mM NaCl (pH 7 9) The reaction was terminated with 20 mM spun <1own (10 min at 9,000 x g) and the unbound clotting factors wereEDTA. Then the mixture was diluted twice with water, brought to pH 6.5 measured in the supernatant
with MES and applied to an SP-Sephadex column (5 x 40 cm), which was
equ i l i b ra ted  w i t h  2U  mM T r i s -MES amd  50  mM NaC l  ( pH  0 .5 .1 .  The
column was eluted with 250 ml of 20 mM Tiis_MeS. à'OOn.'M'N;al Clortingof Fibrinogen
(pH 6.5) to remove other prothrombin degradation products than throm- To 50 pl human fibrinogen (10 mg/ml) were added 50 pl bufferb i n  F i na l l y t he th ro rnb inwase lu tedw i t ha l i nea rg rac l i en to f ( 2x500m l )  ( 175mMNaC l ,50mu t r i s -ÈC t (pH79 ) ,0 .5mg /m lHSAand i f p resen t
200-2.000 mM NaCl in 20 mM MES-Tiis (pH 6 5) Thrombin fractions ào -u cocl..;. The reaction was starred by rhe addition of 100 pl
were dialysed against 175 mM NaCl and 50 mM Tiis-HCl (pH 7 9). thrombin (20-80 nM) The clotting time was detected manually
Bovine factor VIII was purified according to Vehar and Davie (15)
with the modifications of Van Dieijen et al (16). To srandardize the
factor VIII, relèrence curves were made, using congenital iactor Vifi Results
deficient plasma and normal pooled bovine plasma (16)
Protein Concentrations
The molar concentrations of factors IX, IX,, Xr. II, V V, were
calculated from their optical density at 280 nm, their specific absorption
and their molecular weight (12, 13,74, 17).
The concentrations of activated clotting proteases also were cleter_
mined spectrophotometrically from the amidolytic activity (1g). Factor X
was activated with 2 mg/ml RVV-X during 15 min at 37. C prior to
lunctional measurement. Prothrombin was activated with Echis càrinatus
venom (19) and the ensuing thrombin was measured with S223g.
Factor IX was activated with purified conract product (10, l1) and the
factor IX" was measured according to Tâns et al. (20).
Factors V and V, were determined according Lindhout et al (21)
Factor VIII was measured in two ways: A and B.
A: To a mixture of 200 pl phospholipid vesicles (30 pM, 75% DOPC
and 25"/. DOPS), CaCl2 (5 mM) and factor IX" (150 nM) were added
50 prl factor X (2 pM) and CaCl2 (5 mM). Fifteen seconds after the
addition of the factor X, the activated factor VIII was added (50 pl). To
stop the reaction samples of 200 pl were pipetted (afiter 20 sec) into 700 al
20 mM EDTA (in a cuvette). The formetl factor X, was measured bv
addition of 100 pl 52337 (2 mM) and following substrare hydrolysis ai
405 nm. The whole procedure was done aI 37" C ancl the mixturei used
were prewarmed during at least 5 min
B: To a mixture of 250 pl 40 pM phospholipid vesicles (75% DOPC
and25'/" DOPS), 10 mM CaC!, 100 nM factor IXu were added 150 _ x pl
buffer (see below). Then x ptl factor VIII,, were addecl and after 30 sec
100 pl factor X (2 pM) to start the reaction After 30 and 60 sec reaction
time 200 pl-samples were taken ancl the formed factor X, was measured.
In all cases corrections were made for 52331 hydrolysis by thrombin
and factor X" formation by factor IX" in the absence of factor VIII-.
All experiments with the purified clotting factors were performeà in a
buffer containing 175 mM NaCl, 50 mM Tiis-HCl, 0.5 ms/ml HSA(pH 7.0.1
P hos pho I ip ids and Phos pholip id Vesicle s
DOPS was prepared from DOpC according to Comfurius and. Zwaal
(22). Vesicles were prepared by sonication of a phospholipicl mixture of
Binding Experiments
In order to measure the effect of PpS on binding of clotting
factors to phospholipid membranes we first determined the
conditions under which without PPS, 50% of the factor would be
bound. The effect of PPS on the binding of the different factors
has been determined at a range of PpS concentrations (0-20 pg/
ml). In none of the cases PPS prevented binding of the clotting
factor to the phospholipid membranes. ppS in many cases even
slightly promotes this binding, an effect that is most pronounced
for factors Xo and IX^. Tâble 1 shows the results for one ppS
concentration. Because no inhibition of the bindins could be
shown under the above circumstances, the other data are not
shown.
Thrombin-Dependent Activation of Factors V andVIII and
Fibrinogen
Fig. 1 shows the effect of PPS on the activation of factor VIII
by 0.5 nM thrombin In the absence of ppS the maximal amount
of factor VIII" is reached after about 3 min and then the amount
slowly decreases. When PPS is present during the activation, the
rate of factor VIII. formation strongly decreases with increasing
PPS concentrations and the maximal amounts of factor VIII_
formed also are much lower. Half maximal inhibition of the
activation is obtained at about 1 pglml of ppS. An amount of
0.5 nM thrombin activates factor VIII only slowly. In Fig.2 the
factor VIII is activated with 50 nM thrombin. The turnover
numbers in both cases differ quite a lot. In Fig. 1 the number is
23-30 min 1, whereas i t  is in Fig.2 about g00 Àin r.  From these
numbers it can be calculated that after 1 min activation with
0.5 nM thrombin not more than 2o/" of the factor VIII is
activated.
The experiment of Fig. 1 is repeated with 2.5 mg/ml fibrinogen
present in the factor VIII activating mixture. In that case ihe
activation rate of factor VIII is decreased To obtain a same
227
o 2 4 6 8
Act ivot ion t ime (minutes)
Fig I Effect of PPS on the activation of factor VIII by thrombin
Factor VIII (2 nM) was activated (37' C) with 0 5 nM thrombin in the
presence of  5 mM CaCl2 and PPS in concentrar ions of  0 (O),0.5 (a) ,  1
(A), 2 (^) and a (n) pg/ml. The formed factor VIII" was measured after
1 B min activation time: procedure A, see Methods. Corrections were
made for the inhibiting effect of PPS on the factor X-activating reaction
itself To determine this effect, independently from the effect on factor
VIII activation, PPS was added to the factor X activating mixture in the
required concentrations Then factor VIII (2 nM), activated for 4 min
(37'C) in the absence ofPPS, was added to the reaction mixture and the
rate of factor X activation measured
activation rate as in the absence of fibrinosen. about 2 5 times
more thrombin is necessary However, also with fibrinogen
present, PPS still is a very potent inhibitor of lactor VIII
activation ; 0 .5 , I, 2 and 4 pglml PPS cause inhibition percentages
Thble I The effect of PPS on binding of clotting factors to large volume
phospholipid vesicles
Factor Concentration
(nM)
c50
(pM)
AB
( % )
X
xo
IX
IX"
II
VIII
4 I
59
65
58
3 1
96
20
50
37
17.5
445
63
45
600
1 2 6
/ a
+ 2 8
+ 3 7
+ 3 5
L /
+ 7'7
+ t
C50 is the phospholipid concentration at which the binding of the clotting
factors in the absence of PPS is 50% ^B is the change in binding brought
about by 5 pg/ml PPS The binding of the eight clotting factors to the
vesicles was measured at a range of phospholipid concentrations to
determine the phospholipid concentration that causes a 50% binding of
the clotting factor At these phospholipid concentrations the effect ofPPS
was determined Fivc pg PPS per ml were added to phospholipid-clotting
factor-mixtures and the effect of the PPS on the bindins was determined
of 20,39,64 and 81, respectively. These numbers are similar to
the values found in Fig. 1.
Fig.2 shows an experiment in which factor VIII is activated
with 50 nM thrombin for 1 min. Two cases were compared, firstly
PPS was added before the addition of thrombin and secondly it
was added 30 sec after the addition of thrombin. Factor VIII. was
measured by diluting it 100-fold in the factor X activating mixture
(5 pl-sample). The control shows that the PPS present in the 5 pl-
sample does not affect the factor Vlllo-assay When PPS is
present during the whole minute it effectively inhibits, but when it
is added at 30 sec after the thrombin addition (then almost all
factor VIII is activated;point A) it has only a minimal effect. So
we can conclude that PPS inhibits factor VIII activation, but
hardly preformed factor VIII., provided that the PPS is diluted
afterwards.
The effect of PPS on factor V activation is shown in Fig 3. One
can observe that PPS has only a slight inhibitory effect. The effect
of PPS on factor V activation by thrombin is, decreasing the
activation rate and not inhibiting factor Vu. The factor Vo activity
after 2 h activation time was the same for all PPS concentrations.
In Fig. 3 the plateau after 2 h was at 1.6 nM min t. Half maximal
inhibition requires more than 30 pglml of PPS.
The effect of PPS on fibrinogen clotting by thrombin was less
then20"/o under all conditions either in the absence or presence of
5 mM CaC12. ln the absence of CaCl2, 10 and 40 nM thrombin
caused clott ing t imes of 196 and 119 sec, which were not
prolonged by 50 pglml PPS and only for a few seconds with much
higher PPS concentrations (up to 250 Fg/ml) representing an
inhibit ion of less than 1,0"Â.ln the presence of 5 mM CaCl2, the
clotting times were 152 and 39.5 sec, using 10 and 40 nM
thrombin, respectively. Also in this case PPS hardly had an effect.
No change in the clotting times was observed at less than 20 p,glml
PPS and only some prolongation of the clotting time could be
noticed at 50 pgiml PPS: the âbove mentioned clotting times were
20 and 4 sec longer, respectively, representing an inhibition of
1020%.
The EfJect of PPS of the Activation of Factors II and X
We have studied the effect of PPS on the prothrombin
activating complex. In the absence of phospholipid PPS has no
effect on prothrombin activation, however, when phospholipids
are present the activation reaction is somewhat stimulated by PPS
(two-fold). PPS does not affect the complete prothrombin activat-
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Fig.2 EllecI of PPS on activation of factor VIII with 50 nM thrombin
and effect of PPS on activated factor VIII In case (Â) the activation was
started by mixing 20 pl facror VIII (12 nM) with 20 pl thrombin
(100 nM), CaC! (10 mM) At t : 30 sec 20 pl PPS (0-24 pg/ml) were
added, making the final PPS concentrations as indicated in the figure The
PPS solution also contained 5 mM CaCl2 and 50 nM thrombin to keep
these concentrations constant after PPS addition In case (O) the
activation was started by addition of PPS together with thrombin To 40 pl
factor VIII (6 nM) were added 20 pl 150 nM rhrombin, 15 mM CaCl, and
0-24 p,glml PPS. In both cases at t : 60 sec 5 pl-samples were taken and
assayed for factor VIII" (Methods, procedure B) The open triangle (A) is
the result of factor VIII activation with 50 nM thrombin in the presence of
5 mM CaCl and absence of PPS during 30 sec The control (I) shows an
experiment in which 5 pl PPS (0-8 pgiml) were added to the factor VIII,,
assay mixture and the factor VIII was activated with 50 nM thrombin (in
the presence of 5 mM CaCl2) during 60 sec
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Frg. 3 The effect of PPS on activation of factor V by thrombin. Factor V(aZnl|d) was activated with 0.5 nM thrombin, in the presence of 5 mM
CaCl, and PPS in concenrrations of 0 (O), 4 (O), 8 (A), 16 (À) and 32 (!)
pglml. To stop further activation, the mixture was cliluted 1.000_fold in
5 mM CaCl,, before measuring the factor V" formed
ing complex up to 4 pglml and a minor inhibiting effect is noticed
(less than 20%) at higher PPS concentrations So in this case ppS
does not stimulate the reaction rate as we found in the absence of
factor Vu.
In Fig.4A the effect of PPS on factor X activation by
factor IXo is shown, both in the absence of phospholipid vesicles
and in their presence. In the absence of phospholipids there is no
effect, whereas in the presence of phospholipids some activation
of the reaction (80%) is noticed at PPS concentrations of 4-g pgl
ml. This effect is similar to the effect found for prothrombin
activation by factor Xo in the presence of phosphotipids.
Fig 48 shows the effect of PPS on factor X activation by the
complete factor X âctivating complex (factors IXu, VIII. and
phospholipids). In this experiment factor VIII was activated for
30 sec with 100 nM thrombin, which is sufficient for comolete
activation (26) and then the PPS was added together with the
factor X. So the action of PPS in this case is not on the activation
of factor VIII, but on factor VIII" itself A strong inhibiting effect
o f  PPS is  no t iced .
The inhibition of factor VIII. bound in the complete factor X
activating complex depends on both the PPS concentration and
o.2 0.4 0.6 0.8
1/ fFoctor  Vi l t l  (nv-1)
Fig.5 Factor X activation by the complete factor X activating complex
in the absence and presence of PPS. The reaction vessel contained 3 pM
factor IX", 5 mM CaCl2, 20 pM phospholipids, 100 nM thrombin ànd
PPS, present in concentrations of 0 (O), 0.5 (^), 1 (V) and 2 (I) prg/mt.
Before starting the reaction all components were preincubated during
5 min at 37' C. Then 0.2 pM factor X was added (t : 0 min) and at t =
1 min the factor VIII (1-6 nM, i. e 1.45-8 72 Ulml) Samptes were taken
at t : 1 25 min and assayed for factor X, The inset shows that factor X
activation was linear from 5 to 90 sec after the factor VIII addition. The
V.,* was 2.406 nM FX" min-r
the factor VIII, concentration as is shown in Fig. 5. Fig. 5 is a
double reciprocal plot of the factor Xu formation against the
factor VIII concentration at different PPS concentrations.
Straight lines were obtained, which all cross the v-axis at the same
point (0.416 nM-1 min, i .e. 2.406 nM facror Xuîormed per min).
Thus at infinite factor VIII" concentration PPS does not inhibit
the complete factor X activating complex.
Discussion
The binding experiments described in this article show that in
no case PPS prevents binding of a clotting factor to procoagulant
phospholipids. So one may conclude that inhibiting effect of ppS
in blood coagulation is not caused by preventing the formation of
the prothrombin or factor X activating complexes. There even
exists a stimulating effect of PPS on binding of factors IXu and Xo
and to a lesser extent on binding of factors IX, X and V" to
phospholipid membranes (Tâble 1), the reason for this phenome-
non ls not yet clear. This increased binding, moreover, leads to
higher enzymatic activities PPS stimulates - in the presence of
phospholipids - the activation of factors X (Fig.4A) and II by
Fig.4 EffecI of PPS on the factor X activation by factor IX.
Frame A: Activation of factor X by factor IX^ in the absence (O)
and presence (A) of phospholipids. The reaction mixture con-
tained 1 pM factor IX", 5 mM CaCl2, 0-10 pglml ppS and if
present 20 pM phospholipids In the absence of phospholipids the
reactlon was started with 8 pM factor X and in their presence with
2 pM factor X. Samples were taken after 1(t, 20 and 3{J min
reaction time and assayed for factor X" Frame B: Activation of
factor X by the complete factor X activating complex The reac-
tion mixture contained 50 nM factor IX", 100 nM thrombin, 5 mM
CaClr, 20 pM phospholipids, 15 pM factor VIII (added at t : Q
sec) and 0-10 pg/ml PPS + 1 pM factor X, which were added
together at t : 30 sec. Samples were taken at t = 60 and 90 sec and
assayed for factor X.. In all cases before starting the reaction of
the components were preincubatecl  at  37.  C for  5 min
24
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factors IX" and X", respectively. The increased enzymatic activity
very likely is a reflection of the higher local concentration of the
activation enzyme on the phospholipid membrane surface. In the
presence of factor Vu, factor Xo binds much tighter to a phospho-
lipid membrane (27 ,28) than in its absence, so in the presence of
factor Vu PPS has no effect: factor Xu is almost completely bound
and thus more binding leading to a higher enzymatic activity is not
possible. Anyhow the conclusion of Fischer et al. (1) that PPS acts
by inhibiting complex formation seems to be refuted.
In the second part of this study it became clear that PPS
inhibits on the level of factor VIII. About 85% inhibition of
factor VIII activation by thrombin was shown at a PPS concentra-
tion of 4 lt"glml (Fig. 1). In Fig. 1 probably an equilibrium is
reached after a few minutes between the formation of factor VIII.
and the breakdown of factor VIII". If the formation of factor
VIII' from a large factor VIII pool is slow, than the large pool
does not decrease in size, so factor VIII. formation will continue
for several minutes with the same speed. In that case a piateau is
reached depending on formation and breakdown of factor VIII..
When factor VIII' formation is diminished, two effects may be
noticed, the initial rate of factor VIII. formation is lower and the
plateau is on a lower level. So PPS has two effects, it decreases the
initial activation rate and it causes a lower steady state level of
factor VIII,.
The data from Fig. 1 may be interpreted in two ways. Either
factor VIII. is inhibited by PPS or the activation of factor VIII by
thrombin is inhibited by this drug. Fig.2 shows that PPS inhibits
factor VIII activation by thrombin, but does not inactivate
preformed factor VIII.. Combining the results of Figs. 2 and 4B
it is clear that although PPS does not inactivate factor VIII., it
inhibits the function of factor VIII. Factor VIII" probably is
reversibly inhibited by binding to PPS. When a PPS-factor VIII"
complex is diluted sufficiently (100-fold, Fig. 2) factor VIII. gets
back its function.
Factor V activation by thrombin also can be inhibited by PPS,
however, about 3O-fold higher concentrations of PPS are required
to obtain the same inhibiting effect (Fig. 3). Clotting of fibrinogen
by thrombin is hardly inhibited and only then when the PPS
concentration is very high. Probably there is no interaction
between fibrinogen and PPS, for, as was shown, fibrinogen does
not prevent the inhibitory effect of PPS on factor VIII activation
by thrombin.
In Figs.4-5 we showed the effect of PPS on the complete and
incomplete factor X activating complex. The most important
result is the inhibiting effect of PPS on the complete factor X
activating complex (Fig. aB). Under the conditions of Fig. 4B half
maximal inhibition is caused by 4 pg/ml PPS, but from Fig.5 it is
clear that the percentage of inhibition depends on both the PPS
concentration and the factor VIII. concentration. On extrapola-
tion to infinite factor VIII. concentration no inhibition is found at
any PPS concentration, which means that it is not the factor X
activating complex as such that is inhibited by PPS, but one of its
components: factor VIII'. When factor VIII. is present in excess
no inhibition of the complex by PPS is found. Thus PPS has a two-
fold effect, it inhibits factor VIII activation by thrombin and it
inhibits factor VIII. action in the factor X activating complex
probably by reversible binding to factor VIII..
On basis of the result that PPS mainly acts on factor VIII.
activation, one can predict that PPS should have an effect on the
APTT, On starting blood coagulation by contact activation
factor XIu activates factor IX, factor IXu then slowly activates
factor X and finally factor Xu slowly activates prothrombin to
thrombin, which initially is formed in trace amounts. These small
amounts of thrombin activate factor VIII (and also factor V)
slowly When some factor VIII" is present, the complete factor X
activating complex is formed, which will activate factor X rapidly.
) a A
Factor Xu will form with factor V" the complete prothrombinase,
resulting in a burst of thrombin. When factor VIII. formation is
inhibited, factor Xu formation is delayed and moreover factor IXu
is more susceptible to plasma inhibitors in the absence of
factor VIII. than in its presence, so less factor X activating
complex is formed. So PPS makes the APTT longer. The effect of
2 pglml PPS on the APTT in a human system is not very high (3).
From Fig.1 in ref. (3) one can expect a prolongation of the
clotting time of about 10 sec. In plasma, however, many proteins
are present, which may bind PPS, making the free PPS concentra-
tion lower than the total concentration. So the effect of PPS may
be underestimated.
The effect of PPS on the extrinsic blood coagulation should be
Iess than on the intrinsic blood coagulation. On starting blood
coagulation with thromboplastin, factor VII. together with the
tissue factor activates factor X directly and trace amounts of
thrombin will activate factor V (not very much inhibited by PPS),
so the complete prothrombinase is formed independently of the
factor X activating complex.
We conclude that the main antithrombin III independent
inhibitory action of PPS is due to its effects on factor VIII..
Therapeutic concentrations of PPS will not rise higher than 2 p.gl
ml (i) and at this concentration the only antithrombin III
independent action on blood coagulation is that on factor VIII^.
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Summary
We studied the inhibitory effect of pentosan polysulphate
(PPS, Hémoclar@) on thrombin formation in blood coagulation.
In contrast to a current hypothesis (1) the anti thrombin II I
independent effect of PPS on blood coagulation is not caused by
preventing the binding of the factors IX. IX,'. X. X", VIII, V V"
and II  onto procoagulant phospholipids.
We investigated the activation by thrombin of factors I, V and
VIII. A strong inhibitory effect of PPS on factor VIII activation
could be observed Inhibition of the activation of factor V to the
same extent requires about 3O-fold higher concentrat ions of PPS,
whereas the activation (clotting) of fibrinogen is not inhibited.
The effect of PPS on factor VIII" is two-fold: A) it inhibits its
formation and B) it inhibits its function probably by the formation
of a factor VIII"-PPS comPlex.
Prothrombinase, constituted of purified factors X", Vo and
phospholipids was not inhibited by PPS. neither were incomplete
lorms of this enzyme, lacking phospholipids or factor V". The
complete factor X activating enzyme (factors 1X,,. VIII. and
phospholipids), however, was strongly inhibited. but incomplete
forms, lacking factor VIII, were not The inhibition of the
complete enzyme can be explained by reversible binding of PPS to
factor VIII,, (causing an inhibition of its function) and it is not an
effect on the enzymatic function of the complete enzyme. On
saturation of the enzyme with an excess of factor VIII, no
inhibit ion by PPS is noticed.
We postulate therefore that the antithrombin Ill independent
inhibitory effect of PPS on thrombin generation on blood
coagulation is by interaction with factor VIII.. This effect is
additional to the heparin-like action of PPS, i e. potentiation of
the activity of antithrombin III and/or heparin cofactor II At
This work was 1ïnancially supported by the "Centre de Recherches
Clin-Midy" and "La Fondation de France"
Abbrcviations:
s2238. H-D-phenylalanyl-L-pipecolyl-L-arginine-p-nitro-anilide-
dihydrochloride; 52337, N-benzoyl-L-isoleucyl-L-glutamyl-(piperidyl)-
glycyl-L-arginine-p-nitroamlide hydrochloride; RVV-X. FactorX
activator purified fiom Russell's viper venom; Tiis, tris(hydroxymethyl)-
aminomethane; EDTA, ethylenediaminotetraacetic acid; PC, phos-
phatidyl choline ; PS, phosphatidyl serine ; DOPC, 1 ,2-dioleoyl-sn-glycero-
3-phosphocholine ; DOPS, 1,2-dioleoyl-sn-glycero-3-phosphoserine ; STI,
soybean trypsin inhibitor; HSA, human serum albumin; PPS, pentosan
polysulphate (Hémoclar); MES, 2-(N-Morpholino)ethane sulfonic acid;
DEAE, diethylaminoethyl; Qeg, quaternary aminoethyll SB sulfo-
propyl; APTT, Activated partial thromboplastin time
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concentrations attained during therapeutic use the action of
pentosan polysulphate on factor VIII, is the only one that will
significantly inhibit the coagulation mechanism.
Introduction
Pentosan polysulphate (PPS) or Hémoclar@ is a mixture of
polysaccharides that is obtained by sulphation of pentosans
extracted from beech wood shavings (2) Its average molecular
weight is 4,500 (2). Soria et al.  (3) and Scully et al.  (4) have shown
that PPS shows some similarities with low molecuiar weight
heparin as to its inhibitory effect on blood coagulation. Both
compouncls are dependent upon antithrombin III for factor X.
and thrombin inhibiting activities (3, 4). Pentosan polysulphate
also is a good activator of heparin cofactor II (2) Apart from
that, PPS inhibits the partial thromboplastin time independently
of anti thrombin I l l  (1,3). Dunn et at (5) have shown that both
heparin and PPS increase the binding of fibrinogen to ADP-
treated platelets. Fischer et al (1) showed that PPS inhibits the
factor Xu generation in defibrinated plasma triggered by contact
activation as well as by purified factor IXu This suggests that PPS
cloes not act on the contact system, but interferes with factor X
activation at thc level of factor IX^. Both Ofosu et al (6) and
Walker and Esmon (7) have suggested that antithrombin III
independent effects of heparin are due to inhibition of phos-
pholipid binding. Fischer et al.  (1) suggest that PPS acts by the
same mechanism, presumably even more effective than heparin,
because of its greater negative charge Another suggested
mechanism is inhibition of thrombin dependent factor V activa-
tion and thereby inhibiting the prothrombinase complex (8).
From the literature it is clear that the site of inhibition of blood
coagulation by PPS has not been determined unequivocally
Possible sites of action are: The activation of prothrombin by
prothrombinase (factor Xu, factor V" and phospholipid) and the
activation of factor X by its activating eîzynle (factor IX",
factor VIII. and phospbolipid). This inhibition might be mediated
by either impairment of the binding of clotting factors to
phospholipids or direct action on thrombin in the activation of
one more of the factors I, V, and VIIL
Materials and Methods
Materials
Human congenital factor VIII deficient plasma was a gift from T.
Repucci, Centre de Tiansfusion, Liège, Belgium The plasma was from a
patient with less than 1'lo factor VIII The blood (450 ml) was collected in
a bag containing CPDA-formula 1 (63 ml, containing 2 g dextrose mono-
hydrate. 1.66 g sodium citratc, 206 mg citric acid, 158 mg sodium acid
phosphate, 17 3 mg adenine) The blood was centriluged at 5'000 x g
rluring 15 min at 4' C The plasma was frozen at 80' C before use
Bovine factors V and V. were a gift from Dr T. Lindhout 52337 ' 52238,
RW-X and human fibrinogen (grade L) were purchased from AB Kabi
Diagnostica, Stockholm. Sweden. STI, HSA (essentially fatty acid free),
heparin (sodium salt) and Echis carinatus venom were obtained from
Sigma Sephadex G50, DEAE-Sephadex and SP-Sephadex were from
Pharmacia, Tiasylol was from Bayer Actin activated cephaloplastin
reagent was from Dade Diagnostics and Reptilase from Boehringer
Mannheim Hémoclar was a gift of the Laboratoires Clin Midy, paris,
France
All other reagents used, were of the highest grade commercially
available.
Proteins
Bovine factor lX was purified according to Fujikawa et al (9)
Factor IXo was prepared by incubating bovine factor IX with purified
contact product (10, l1) according to Fujikawa et al (12)
Bovine lactors X, and X, were prepared according to Fujikawa et al
(13) The two forms of factor X were well separated In this study
factor X, is used, which is not indicated further No thrombin or factor X"
could be detected in our factor X preparations as determined with the
chromogenic substrates S2238 and S2337, respectively Bovine prothrom-
bin was purified as described by Owen et al (14) Thrombin was prepared
by incubating 5 pM prothrombin with 10 pM phospholipid vesicles (25%
brain PS, 75% yolk PC), 10 mM CaCl,, 30 nM factor X" and 21 nM
factor V, during 40 min at 37' C in a buffer containing 40 mM MES-Tiis
and 100 mM NaCl (pH 7 9) The reaction was terminated with 20 mM
EDTA. Then the mixture was diluted twice with water, brought to pH 6.5
with MES and applied to an SP-Sephadex column (5 x 40 cm), which was
equilibrated with 20 mM Tiis-ME,S amd 50 mM NaCl (pH 6 5). The
column was eiuted with 250 ml of 20 mM Tïis-MES. 200 mM NaCl
(pH 6.5) to remove other prothrombin degradation products than throm-
bin Finally the thrombin was eluted with a linear gradient of (2 x 500 ml)
2001,000 mM NaCl in 20 mM MES-Tïis (pH 6 5) Thrombin fractions
were dialysed against 175 mM NaCl and 50 mM Tiis-HCl (pH 7 9)
Bovine factor VIII was purified acoordrng to Vehar and Davie (15)
with the modilications of Van Dieijen et al. (16) To standardize the
factor VIII, reference curves were made, using congenital factor VIII
deficient plasma and normal pooled bovine plasma (1o.;
P r o tein C o ncentr atio ns
The molar concentrations of factors IX, IX,, Xr, Il, V V" were
calculated from their optical density at 280 nm, their specific absorption
and their  molecular  weight  (12,  13,14,77).
The concentrations of activated clotting proteases also wcre deter-
mined spectrophotometrically from the amidolytic activity (18). Factor X
was activated with 2 mg/ml RVV-X during 15 min at 37. C prior to
functional measurement Prothrombin was activated with Echis carinatus
venom (19) and the ensuing thrombin was measured with 52238.
Factor IX was activated with purified contact product (10, 11) and the
factor IX, was measured according to Tâns et al (20)
Factors V and V" were determined according Lindhout et al (21).
Factor VIII was measured in two ways: A and B
A: To a mixture of 200 pl phospholipid vesicles (30 pM, 15% DOPC
and 25"/" DOPS), CaCl, (5 mM) and facror IX^ (150 nM) were added
-50 pl factor X (2 pM) and CaCl2 (5 mM). Fifteen seconds afrer rhe
addition of the factor X, the activated factor VIII was added (50 pl) To
stop the reaction samples of 200 pl were pipetted (after 20 sec) into 700 pl
20 mM EDTA (in a cuvette) The formed factor X, was measure<i by
addition of 100 pl 52337 (2 mM) and following substrate hydrolysis at
405 nm. The whole procedure was done at 31" C and the mixtures used
were prewarmed during at least 5 min.
B: To a mixture of 250 pl 40 pLM phospholipid vesicles (75% DOPC
and25"k DOPS), 10 mM CaCl2, 100 nM factor IX, were addecl 150 - x ul
buffer (see below) Then x pl factor VIII" were added and after 30 sec
100 pl factor X (2 pM) to srart the reaction. After 30 and 60 sec reaction
time 200 pl-samples were taken and the formed factor X,, was measured
In all cases corrections were made for 52337 hydrolysis by thrombin
and factor X. formation by factor IX" in the absence of factor VIII"
All experiments with the purified clotting factors were performed in a
buffer containing 175 mM NaCl, 50 mM Tiis-HCl. 0 5 ms/ml HSA(pH 7 e)
P ho s pho lip ids and P hosp ho lip id Ve sic le s
DOPS was prepared from DOPC according to Comfurius and Zwaal
(22). Vesicles were prepared by sonication of a phospholipid mixture of
25% DOPS and'75'k DOPC using an MSE Mark II 150-Watr ulrrasonic
disintegrator, set at 9 F peak to peak amplitude, or by the ether-injection
method according to Van de Steen et al (23) and Deamer and Bangham
Ql By injection of 2 ml ether, containing 3 pmol DOPC and 1 pLmol
DOPS into 4 ml warm (60" C) buffer (175 mM NaCl, 50 mM Tiis-HCl;
pH 7.9) large unilamellar vesicles were obtained. The vesicles were
dialyzed against the same buffer to remove traces of ether To concentrâte
the vesicles and to remove small vesicles which cannot be spun down, they
were centrifuged at 6,000 x g during 10 min The supcrnatant was
discarded, the pellet suspended into the same buffer and again the vesicles
were spun down Finally the pellet was taken up into a small amount of
buffer. These vcsicles were used in the binding studies.
Phospholipid concentrations were determined by analysis of the
phosphate content (25)
Binding Experiments
Binding of clotting factors to large unilamellar vesicles was measured in
the following way Clotting factors (20-100 nM) were incubated in the
presence of 5 mM CaCl2 with various concentrations of large-volume-
vesicles containing 25% DOPS and 75ok DOPC Then the vesicles were
spun down (10 min at 9,000 x g) and the unbound clotting factors were
measured in the supernatant
Clotting of Fibrinogen
To 50 pl human fibrinogen (10 mg/ml) were added 50 pl buffer
(175 mM NaCl, 50 mM Tiis-HCl (pH 7 9), 0.5 mg/ml HSA and if present
20 mM CaCl). The reaction was started by the addition of 100 pl
thrombin (20-80 nM) The clotting time was detected manually
Results
Binding Experiments
In order to measure the effect of PPS on binding of clotting
factors to phospholipid membranes we first determined the
conditions under which without PPS, 50% of the factor would be
bound. The effect of PPS on the binding of the different factors
has been determined at a range of PPS concentrations (0-20 pg/
ml). In none of the cases PPS prevented binding of the clotting
factor to the phospholipid membranes. PPS in many cases even
slightly promotes this binding, an effect that is most pronounced
for factors Xo and IX". Tâble 1 shows the results for one ppS
concentration. Because no inhibition of the binding could be
shown under the above circumstances. the other data are not
shown.
Thrombin-Dependent Activation of Factors V andVIII and
Fibrinogen
Fig 1 shows the effect of PPS on the activation of factor VIII
by 0.5 nM thrombin. In the absence of PPS the maximal amount
of factor VIII" is reached after about 3 min and then the amount
slowly decreases. When PPS is present during the activation, the
rate of factor VIII. formation strongly decreases with increasing
PPS concentrations and the maximal amounts of factor VIII"
formed also are much lower. Half maximal inhibition of the
activation is obtained at about 1 pglml of PPS An amount of
0.5 nM thrombin activates factor VIII only slowly. ln Fig.2 the
factor VIII is activated with 50 nM thrombin The turnover
numbers in both cases differ quite a lot. In Fie. 1 the number is
23-30 min 1, whereas i t  is in Ég.2 about S00 Àin 1. From these
numbers it can be caiculated that after 1 min activation with
0.5 nM thrombin not more Than 2"/" of the factor VIII is
âctivated.
The experiment of Fig. 1 is repeated with 2.5 mg/ml fibrinogen
present in the factor VIII activating mixture. In that case the
activation rate of factor VIII is decreased. To obtain a same
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1 2 Thble I The effect of PPS on binding of clotting factors to large volume
phospholipid vesicles
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Fig I Efïect of PPS on the activation of factor VIII by thrombin.
Factor VIII (2 nM) was activared (37' C) with 0 5 nM thrombin in the
presence of 5 mM CaCl, and PPS in concentrations of 0 (O), 0 5 (a), l
(A), 2 (^) and 4 (!) pg/ml. The formed factor VIII,, was measured after
1 8 min activation time: procedure A, see Methods Corrections were
made for the inhibiting effect of PPS on the factor X-activating reaction
itself. To determine this effect. independently from the effect on factor
VIII activation, PPS was added to the factor X activating mixture in the
required concentrations. Then factor VIII (2 nM), activated for 4 min
(37' C) in the absence of PPS, was added to the reaction mixture and the
rate of factor X activation measured
activation rate as in the absence of fibrinosen. about 2.5 times
more thrombin is necessary. However, also with fibrinogen
present, PPS still is a very potent inhibitor of factor VIII
activation ; 0.5 , |, 2 and 4 pg/ml PPS cause inhibition percentages
C50 is the phospholipid concentration at which the binding of the clotting
factors in the absence of PPS is 50% ^B is the change in binding brought
about by 5 pg/ml PPS The binding of the eight clotting factors to the
vesicles was measured at a range of phospholipid concentrations to
determine the phospholipid concentration that causes a 50% binding of
the clotting factor. At these phospholipid concentrations the effect of PPS
was determined Five pg PPS per ml were added to phospholipid-clotting
factor-mixtures and the etïect of the PPS on the bindins was determined.
of 20,39,64 and 81, respectively. These numbers are similar to
the values found in Fig. 1.
Fig. 2 shows an experiment in which factor VIII is activated
with 50 nM thrombin for 1 min. Two cases were compared, firstly
PPS was added before the addition of thrombin and secondly it
was added 30 sec after the addition of thrombin Factor VIII, was
measured by diluting it 100-fold in the factor X activating mixture
(5 pl-sample) The control shows that the PPS present in the 5 prl-
sample does not affect the factor Vlllu-assay. When PPS is
present during the whole minute it effectively inhibits, but when it
is added at 30 sec after the thrombin addition (then almost all
factor VIII is activated;point A) it has only a minimal effect. So
we can conclude that PPS inhibits factor VIII activation, but
hardly preformed factor VIII", provided that the PPS is diluted
afterwards.
The effect of PPS on factor V activation is shown in Fig. 3. One
can observe that PPS has only a slight inhibitory effect. The effect
of PPS on factor V activation by thrombin is, decreasing the
activation rate and not inhibiting factor Vn. The factor V" activity
aÏter 2 h activation time was the same for all PPS concentrations
In Fig. 3 the plateau affer Z h was at 1.6 nM min 1. Half maximal
inhibition requires more than 30 pg/ml of PPS.
The effect of PPS on fibrinogen clotting by thrombin was less
lhen20oÂ under all conditions either in the absence or presence of
5 mM CaCl2. In the absence of CaCl2, 10 and 40 nM thrombin
caused clotting times of 196 and 119 sec, which were not
prolonged by 50 pg/ml PPS and only for a few seconds with much
higher PPS concentrations (up to 250 pg/ml) representing an
inhibition of less than 10% In the presence of 5 mM CaCl2, the
clotting times were 152 and 39.5 sec, using 10 and 40 nM
thrombin, respectively. Also in this case PPS hardly had an effect.
No change in the clotting times was observed at less than 20 pglml
PPS and only some prolongation of the clotting time could be
noticed at 50 pg/ml PPS: the âbove mentioned clotting times were
20 and 4 sec longer, respectively, representing an inhibition of
10-20%.
The Effect of PPS of the Activation of Factors II and X
We have studied the effect of PPS on the prothrombin
activating complex. In the absence of phospholipid PPS has no
effect on prothrombin activation, however, when phospholipids
are present the activation reaction is somewhat stimulated by PPS
(two-fold). PPS does not affect the complete prothrombin activat-
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Fig 2 Effect of PPS on activation of factor VIII with 50 nM thrombin
and effect of PPS on activated factor VIII. In case (Â) the activation was
started by mixing 20 pl factor VIII (12 nM) with 20 prl thrombin
(100 nM), CaCl, (10 mM). At t - 30 sec 20 pl PPS (0-24 prg/ml) were
added, making the final PPS concentratlons as indicated in the figure The
PPS solution also contained 5 mM CaCl2 and 50 nM thrombin to kcep
these concentrations constant after PPS addition. In case (O) the
activation was started by addition of PPS together with thrombin To 40 pl
factor VIII (6 nM) were added 20 pl 150 nM thrombin, 15 mM CaCl" and
0-24 pg/ml PPS In both cases at t : 60 sec 5 pLl-samples were taken and
assayed for factor VIII" (Methods, procedure B). The open triangle (A) is
the result of factor VIII activation with 50 nM thrombin in the presence of
5 mM CaCl2 and absence of PPS during 30 sec. The control (l) shows an
experiment in which 5 pl PPS (0-8 prgiml) were added to the factor VIII,,
assay mixture and the factor VIII was activated with 50 nM thrombin (in
the presence of 5 mM CaCl,) during 60 sec
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Flg 3 The effect of PPS on activation of factor V by thrombin. Factor V
(42 nl'{) was activated with 0 5 nM thrombin, in the presence of 5 mM
CaCI,  and PPS in concentrat ions of  0 (O),  4 (O),  8 (A),  16 (r )  and 32 ( ! )
pg/ml To stop further activation, the mixture was diluted 1,000-fold in
5 mM CaCl2, before measuring the factor V, formed
ing complex up to 4 pglml and a minor inhibiting effect is noticed
(less than 20%) at higher PPS concentrations. So in this case PPS
does not stimulate the reaction rate as we found in the absence of
factor Vu.
In Fig.4A the effect of PPS on factor X activation by
factor IXo is shown, both in the absence of phospholipid vesicles
and in their presence. In the absence of phospholipids there is no
effect, whereas in the presence of phospholipids some activation
of the reaction (80%) is noticed at PPS concentrations of 4-8 pgl
ml. This effect is similar to the effect found for prothrombin
activation by factor Xo in the presence of phospholipids.
Fig. 48 shows the effect of PPS on factor X activation by the
complete factor X activating complex (factors IXu, VIII. and
phospholipids). In this experiment factor VIII was activated for
30 sec with 100 nM thrombin, which is sufficient for complete
activation (26) and then the PPS was added together with the
factor X. So the action of PPS in this case is not on the activation
of factor VIII, but on factor VIII" itself. A strong inhibiting effect
of PPS is noticed.
The inhibition of factor VIII" bound in the complete factor X
activating complex depends on both the PPS concentration and
o.2 0.4 0.6 0.8
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Flg 5 Factor X activation by the complete factor X activating complex
in the absence and presence of PPS. The reaction vessel contained 3 pM
factor IX", 5 mM CaCl2, 20 pM phospholipids, 100 nM thrombin and
PPS, present in concentrat ions of  0 (O),0.5 (  ) ,  1(V) and 2( l )  pglml
Before starting the reaction all components were preincubated during
5 min at 37" C. Then 0 2 pM factor X was added (t : 0 min) and at t :
1 min the factor VIII (1-6 nM, i.e. 1.45-8.72 U/ml). Samples were taken
at t : 1 25 min and assayed for factor X, The inset shows that factor X
activation was linear from 5 to 90 sec after the factor VIII addition. The
V.u* was 2.406 nM FXo min t
the factor VIII. concentration as is shown in Fig. 5. Fig.5 is a
double reciprocal plot of the factor Xu formation against the
factor VIII concentration al different PPS concentrations.
Straight lines were obtained, which all cross the y-axis at the same
point  (0.416 nM I  min,  i .e.2.406 nM factor  Xo formed per min) .
Thus at infinite factor VIII, concentration PPS does not inhibit
the complete factor X activating complex.
Discussion
The binding experiments described in this article show that in
no case PPS prevents binding of a clotting factor to procoagulant
phospholipids So one may conclude that inhibiting effect of PPS
in blood coagulation is not caused by preventing the formation of
the prothrombin or factor X activating complexes. There even
exists a stimulating effect of PPS on binding of factors IXu and Xu
and to a lesser extent on binding of factors IX, X and V" to
phospholipid membranes (Tâble 1), the reason for this phenome-
non is not yet clear. This increased binding, moreover, leads to
higher enzymatic activities. PPS stimulates - in the presence of
phospholipids - the activation of lactors X (Fig. 4A) and II by
Fig- 4 Eïlect of PPS on the factor X activation by factor IX".
Frame A: Activation of factor X by factor lX" in the absence (O)
and presence (A) of phospholipids The reaction mixture con-
tained 1 pM factor IX,, 5 mM CaCl, 0-10 pglml PPS and if
present 20 pM phospholipids. In the absence of phospholipids the
reaction was started with 8 pM factor X and in their presence with
2 pM factor X Samples were taken after 10, 20 and 30 min
reaction time and assayed for factor Xo Frame B: Activation of
factor X by the complete factor X activating complex The reac-
tion mixture contained 50 nM factor IX", 100 nM thrombin, 5 mM
CaClt,20 pM phospholipids, 15 pM factor VIII (added at t : 0
sec) and 0-10 pg/ml PPS + 1 pM factor X, which were added
together at t : 30 sec Samples were taken at t : 60 and 90 sec and
assayed for factor X". In all cases before starting the reaction of
the components were preincubated at 37' C for 5 min
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factors IXu and Xu, respectively. The increased enzymatic activity
very likely is a reflection of the higher local concentration of the
activation enzyme on the phospholipid membrane surface. In the
presence of factor Vu, factor Xn binds much tighter to a phospho-
lipid membrane (27 ,28) than in its absence, so in the presence of
factor Vn PPS has no effect: factor Xu is almost completely bound
and thus more binding leading to a higher enzymatic activity is not
possible. Anyhow the conclusion ofFischer et al. (1) that PPS acts
by inhibiting complex formation seems to be refuted.
In the second part of this study it became clear that PPS
inhibits on the level of factor VIIL About 85% inhibition of
factor VIII activation by thrombin was shown at a PPS concentra-
tion of 4 ptglml (Fig. 1). In Fig. 1 probably an equilibrium is
reached after a few minutes between the formation of factor VIII.
and the breakdown of factor VIII^. If the formation of factor
VIII. from a large factor VIII pool is slow, than the large pool
does not decrease in size, so factor VIII. formation will continue
for several minutes with the same speed. In that case a plateau is
reached depending on formation and breakdown of factor VIII..
When factor VIII. formation is diminished, two effects may be
noticed, the initial rate of factor VIII. formation is lower and the
plateau is on a lower level So PPS has two effects, it decreases the
initial activation rate and it causes a lower steady state level of
factor VIIIo.
The data from Fig. 1 may be interpreted in two ways. Either
factor VIII, is inhibited by PPS or the activation of factor VIII by
thrombin is inhibited by this drug. Fig.2 shows that PPS inhibits
factor VIII activation by thrombin, but does not inactivate
preformed factor VIII'. Combining the results of Figs. 2 and 4B
it is clear that although PPS does not inactivate factor VIII., it
inhibits the function of factor VIII.. Factor VIII" probably is
reversibly inhibited by binding to PPS. When a PPS-lactor VIII"
complex is diluted sufficiently (100-fold, Fig.2) factor VIII^ gets
back its function.
Factor V activation by thrombin also can be inhibited by PPS,
however, about 30-fold higher concentrations of PPS are required
to obtain the same inhibiting effect (Fig. 3). Clotting of fibrinogen
by thrombin is hardly inhibited and only then when the PPS
concentration is very high Probably there is no interaction
between fibrinogen and PPS, for, as was shown, fibrinogen does
not prevent the inhibitory effect of PPS on factor VIII activation
by thrombin.
In Figs.4-5 we showed the effect of PPS on the complete and
incomplete factor X activating complex. The most important
result is the inhibiting effect of PPS on the complete factor X
activating complex (Fig aB). Under the conditions of Fig. 4B half
maximal inhibition is caused by 4 pglml PPS, but from Fig.5 it is
clear that the percentage of inhibition depends on both the PPS
concentration and the factor VIII. concentration. On extrapola-
tion to infinite factor VIII. concentration no inhibition is found at
any PPS concentration, which means that it is not the factor X
activating complex as such that is inhibited by PPS, but one of its
components: factor VIII.. When factor VIII" is present in excess
no inhibition of the complex by PPS is found. Thus PPS has a two-
fold effect, it inhibits factor VIII activation by thrombin and it
inhibits factor VIII. action in the factor X activating complex
probably by reversible binding to factor VIII..
On basis of the result that PPS mainly acts on factor VIII.
activation, one can predict that PPS should have an effect on the
APTT, On starting blood coagulation by contact activation
factor XIu activates factor IX, factor IXo then slowly activates
factor X and finally factor Xo slowly activates prothrombin to
thrombin, which initially is formed in trace amounts. These small
amounts of thrombin activate factor VIII (and also factor V)
slowly. When some factor VIII" is present, the complete factor X
activating complex is formed, which will activate factor X rapidly.
1 a A
Factor Xu will form with factor V" the complete prothrombinase,
resulting in a burst of thrombin. When factor VIII. formation is
inhibited, factor Xu formation is delayed and moreover factor IXu
is more susceptible to plasma inhibitors in the absence of
factor VIII^ than in its presence, so less factor X activating
complex is formed. So PPS makes the APTT longer The effect of
2 pglml PPS on the APTT in a human system is not very high (3).
From Fig.1 in ref. (3) one can expect a prolongation of the
clotting time of about 10 sec. In plasma, however. many proteins
are present, which may bind PPS, making the free PPS concentra-
tion lower than the total concentration. So the effect of PPS may
be underestimated.
The effect of PPS on the extrinsic blood coagulation should be
less than on the intrinsic blood coagulation. On starting blood
coagulation with thromboplastin, factor VII. together with the
tissue factor activates factor X directly and trace amounts of
thrombin will activate factor V (not very much inhibited by PPS),
so the complete prothrombinase is formed independently of the
factor X activating complex
We conclude that the main antithrombin III independent
inhibitory action of PPS is due to its effects on factor VIII..
Therapeutic concentrations of PPS will not rise higher than 2 p.gl
ml (1) and at this concentration the only antithrombin III
independent action on blood coagulation is that on factor VIII..
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